In the News

Everyone Wants to Kill the Generic Drug Loophole - Except Drug Makers and Some GOP Leaders 

- Boston Globe

What’s Harder Than Making Copycat Biotech Drugs? Selling Them
- Bloomberg

Biosimilars Can Bend the Drug Cost Curve, but Only if Patients Have Access
- Morning Consult

Biosimilar Makers To Congress: Time To Act On REMS Legislation
- Biosimilar Development

The Edison of Medicine
- Harvard Business Review

FDA proposal on biotech drugs sparks criticism
- The Hill Extra

Three Times a Charm
- BioCentury Innovations

Here are 13 local cancer biotechs hoping to make waves next month
- Boston Business Journal

Biosimilars Council Announces 2016 Board of Directors
- Generic Pharmaceutical Association

Implications Of Biosimilars In 2016
- Biosimilar Development

Momenta Pharmaceuticals: How To Unlock The "Black Box" Of Biosimilars
- Biosimilar Development

Globe 100: Recipe for success at Momenta
- The Boston Globe

How the launch of Glatopa transforms Momenta from a 'one-trick pony'
- Boston Business Journal

First generic multiple sclerosis drug, made in Cambridge, launches
- Boston Business Journal

Momenta Applauds FDA Denial of Citizen Petition Requesting FDA Mandate of Information Sharing in Biosimilars Review Process
- Momenta Media Advisory

Last Updated 3/28/2018